A new study published in the JAMA has revealed that for patients with relapsing-remitting multiple sclerosis (RRMS), high-dose immunosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) is related with sustained remission and improvements in neurologic function. Most patients with RRMS who received disease-modifying therapies experience breakthrough disease. Autologous (i.e. using a patient's own cells) HCT has been studied in RRMS with the ...
via Medindia Health News
More READ
No comments:
Post a Comment